RxDoctor Payments Data

Rodney Remington, MD

Ophthalmology · Fresno, CANPI 1831151612

Payments from drug & device makers

$2,892in general payments, 2019–2025

Across 142 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$759
  • AbbVie$636
  • Aerie Pharmaceuticals, Inc.$350
  • Alcon$318
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$195
  • Eyevance Pharmaceuticals LLC$189
  • plus $446 from 11 others

What the payments were for

  • Food & beverage$2,87499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,892 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$1,044,945
Medicare patients
2,191
Services billed
7,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate91$60,924
LumiganBimatoprost95$51,745
Latanoprost2,857$40,030
RocklatanNetarsudil Mesylat/Latanoprost34$31,076
Prednisolone Acetate571$23,650
SimbrinzaBrinzolamide/Brimonidine Tart72$22,954
VyzultaLatanoprostene Bunod32$18,941
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat777$15,732
CombiganBrimonidine Tartrate/Timolol21$13,702
Travoprost97$12,407
Brinzolamide45$9,838
ProlensaBromfenac Sodium26$8,857
IlevroNepafenac24$8,312
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$7,463
Bromfenac Sodium42$6,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$350$92,001125 claims
AbbVieLumigan, Combigan, Alphagan P$636$71,561130 claims
AlconSimbrinza$318$22,95472 claims
Bausch & Lomb Americas Inc.Vyzulta$141$18,94132 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate$195$15,44557 claims
NovartisIlevro, Travatan Z$16$13,42035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →